Targeted Medical Pharma begins clinical trial of new medical food for Autism Spectrum Disorders, with impaired absorption and increased nutritional requirements
Sep 02, 2013 (M2 EQUITYBITES via COMTEX) --
Biotechnology company Targeted Medical Pharma Inc (OTC BB:TRGM) reported on Friday the start of a clinical trial of a new medical food indicated for the dietary management of Autism and Autism Spectrum Disorders.
The company's open label trial will measure the changes in blood concentrations of specific amino acids, behavior, mood, and sleep patterns over a 30 day period following a twice daily oral administration of its new medical food. Subjects will be screened for enrollment based on medical history and diagnosis of Autism or any Autism Spectrum Disorders.
According to the company, its targeted cellular technology is a patented five-step process that is the foundation for its medical foods. This technology promotes the rapid cellular uptake, conversion and release of neurotransmitter precursors, prevents attenuation and increases the efficacy of milligram quantities of amino acids, nutrients and biogenic amines.
Autism and Autism Spectrum Disorders affect 1% of the population of children in the US ages three to 17, with an estimated prevalence of one out of 88 births in the US being affected by the disease.
Comments on this story may be sent to firstname.lastname@example.org
[ Back To Technology News's Homepage ]